Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in <scp>NMRI</scp>‐<scp>Foxn1^nu</scp> mice

Abstract

Treatment with sorafenib led to a potent inhibition of cell viability, tumour progression and angiogenesis. Sorafenib might therefore also be a promising treatment option for high risk or recurrent HB.